NasdaqCM:ORGO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States.


Snowflake Analysis

Concerning outlook with worrying balance sheet.


Similar Companies

Share Price & News

How has Organogenesis Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORGO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

23.7%

ORGO

0.5%

US Biotechs

3.0%

US Market


1 Year Return

-38.8%

ORGO

27.3%

US Biotechs

9.9%

US Market

Return vs Industry: ORGO underperformed the US Biotechs industry which returned 27.6% over the past year.

Return vs Market: ORGO underperformed the US Market which returned 9.5% over the past year.


Shareholder returns

ORGOIndustryMarket
7 Day23.7%0.5%3.0%
30 Day17.0%9.2%8.2%
90 Day2.2%12.8%0.4%
1 Year-38.8%-38.8%28.6%27.3%12.4%9.9%
3 Yearn/a34.7%30.2%31.0%22.3%
5 Yearn/a-1.9%-7.8%58.1%40.3%

Price Volatility Vs. Market

How volatile is Organogenesis Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Organogenesis Holdings undervalued compared to its fair value and its price relative to the market?

10.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORGO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ORGO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ORGO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ORGO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORGO is overvalued based on its PB Ratio (10.8x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Organogenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

24.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORGO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ORGO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ORGO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ORGO's revenue (11.6% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ORGO's revenue (11.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORGO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Organogenesis Holdings performed over the past 5 years?

-19.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORGO is currently unprofitable.

Growing Profit Margin: ORGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORGO is unprofitable, and losses have increased over the past 5 years at a rate of -19.8% per year.

Accelerating Growth: Unable to compare ORGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ORGO has a negative Return on Equity (-102%), as it is currently unprofitable.


Next Steps

Financial Health

How is Organogenesis Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ORGO's short term assets ($111.4M) exceed its short term liabilities ($54.8M).

Long Term Liabilities: ORGO's short term assets ($111.4M) do not cover its long term liabilities ($113.2M).


Debt to Equity History and Analysis

Debt Level: ORGO's debt to equity ratio (230.9%) is considered high.

Reducing Debt: Insufficient data to determine if ORGO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORGO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ORGO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.5% each year


Next Steps

Dividend

What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Gary Gillheeney (64yo)

6.33yrs

Tenure

US$1,437,452

Compensation

Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Inc., since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organogenesis's ...


CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD1.44M) is below average for companies of similar size in the US market ($USD2.21M).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Gary Gillheeney
President6.33yrsUS$1.44m0.38% $1.6m
Lori Freedman
VP & General Counsel3.33yrsUS$508.71kno data
Brian Grow
Chief Commercial Officer2.58yrsUS$605.80k0.0031% $13.5k
Timothy Cunningham
Chief Financial Officer3.58yrsno datano data
Patrick Bilbo
Chief Operating Officer2.58yrsno data0.11% $503.0k
Thomas Pearl
Vice President of Human Resources1.83yrsno datano data
Zorina Pitkin
Senior Vice President of Quality Systems12.33yrsno datano data

3.3yrs

Average Tenure

57yo

Average Age

Experienced Management: ORGO's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gary Gillheeney
President6.33yrsUS$1.44m0.38% $1.6m
Albert Erani
Director1.42yrsno data7.5% $32.9m
Glenn Nussdorf
Director1.42yrsno data14.08% $61.7m
Alan Ades
Chairman of the Boardno datano data8.94% $39.2m
Wayne Mackie
Director1.42yrsUS$150.00k0.094% $413.0k
Arthur Leibowitz
Director1.42yrsUS$150.00k0.0047% $20.6k
Joshua Tamaroff
Director1.42yrsUS$55.00kno data
Maurice Ades
Director1.42yrsno datano data

1.4yrs

Average Tenure

65yo

Average Age

Experienced Board: ORGO's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.


Top Shareholders

Company Information

Organogenesis Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Organogenesis Holdings Inc.
  • Ticker: ORGO
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$438.226m
  • Shares outstanding: 106.11m
  • Website: https://organogenesis.com

Number of Employees


Location

  • Organogenesis Holdings Inc.
  • 85 Dan Road
  • Canton
  • Massachusetts
  • 2021
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORGONasdaqCM (Nasdaq Capital Market)YesClass A Common StockUSUSDJan 2019
2PQDB (Deutsche Boerse AG)YesClass A Common StockDEEURJan 2019

Biography

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company’s advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company’s pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/31 06:44
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.